Their study, using two independent cohorts, found a prognostic value of circulating miR-145 (Trastuzumab at week 2; AUC 0.81) and miR-195 (Lapatinib + Trastuzumab at week 2; not included in the final multivariate model) in predicting pCR in Her2+ breast cancer patients [26]. The gene discussed is ERBB2; the disease is breast carcinoma.